Ignite Creation Date:
2025-12-24 @ 4:58 PM
Ignite Modification Date:
2025-12-28 @ 9:51 PM
Study NCT ID:
NCT06171750
Status:
RECRUITING
Last Update Posted:
2025-07-18
First Post:
2023-11-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Sponsor:
Ankyra Therapeutics, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-01-19
Start Date Type:
ACTUAL
Primary Completion Date:
2027-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-29
First Submit QC Date:
None
Study First Post Date:
2023-12-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-16
Last Update Post Date:
2025-07-18
Last Update Post Date Type:
ACTUAL